WallStSmart
ACLX

Arcellx Inc

NASDAQ: ACLX · HEALTHCARE · BIOTECHNOLOGY

$115.07
+0.00% today

Updated 2026-04-28

Market cap
$6.73B
P/E ratio
P/S ratio
302.04x
EPS (TTM)
$-4.07
Dividend yield
52W range
$48 – $115
Volume
2.8M

Arcellx Inc (ACLX) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item2018201920202021202220232024
Total assets$15.81M$43.59M$57.69M$128.78M$313.82M$825.13M$711.33M
Cash & equivalents
Current assets$14.63M$38.07M$49.36M$112.81M$266.86M$716.36M$599.31M
Total liabilities$1.82M$76.33M$7.15M$250.30M$108.86M$339.75M$256.54M
Current liabilities$1.82M$3.04M$5.27M$14.85M$56.69M$118.24M$125.41M
Long-term debt
Shareholder equity
Retained earnings$-15.07M$-33.05M$-65.14M$-130.11M$-318.79M$-389.48M$-496.83M
Accounts receivable
Inventory
Goodwill

Frequently asked questions

What is Arcellx Inc's revenue?

Arcellx Inc's trailing twelve-month revenue is $22.29M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is ACLX?

In its most recent fiscal year, ACLX ran a gross margin of 70.03%, an operating margin of -1,135.61%, and a net margin of -1,027.25%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ACLX generate?

ACLX produced $-212.59M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.